Search results
Showing 241 to 255 of 317 results for breast cancer
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
We have moved interventional procedures guidance 147 to become HealthTech guidance 93. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Early and locally advanced breast cancer: diagnosis and treatment (CG80)
This guideline has been updated and replaced by NICE guideline NG101.
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development Reference number: GID-TA10592 Expected publication date: TBC
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
April 2026: This Medtech innovation briefing has been withdrawn because the L-Dex U400 device is no longer available in the UK.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Interventional procedures, IPG296 - Issued: April 2009 --> We have moved interventional procedures guidance 296 to become HealthTech guidance 188. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Discontinued Reference number: GID-TA11411
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.
Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101.
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.